Standard

ЗНАЧИМЫЙ РЕГРЕСС ГЛИОБЛАСТОМЫ С НИЗКОЙ ЭКСПРЕССИЕЙ ГЕНА MGMT ПРИ ХИМИОЛУЧЕВОЙ ТЕРАПИИ. / Matsko, M. V.; Luchin, E. I.; Iyevleva, A. G.; Bakholdin, D. V.; Abysheva, S. N.; Zavgorodnyaya, E. V.; Potapova, O. N.; Imyanitov, E. N.; Ulitin, A. Yu; Matsko, D. E.

в: Voprosy Onkologii, Том 57, № 2, 13.07.2011, стр. 245-249.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Matsko, MV, Luchin, EI, Iyevleva, AG, Bakholdin, DV, Abysheva, SN, Zavgorodnyaya, EV, Potapova, ON, Imyanitov, EN, Ulitin, AY & Matsko, DE 2011, 'ЗНАЧИМЫЙ РЕГРЕСС ГЛИОБЛАСТОМЫ С НИЗКОЙ ЭКСПРЕССИЕЙ ГЕНА MGMT ПРИ ХИМИОЛУЧЕВОЙ ТЕРАПИИ', Voprosy Onkologii, Том. 57, № 2, стр. 245-249.

APA

Matsko, M. V., Luchin, E. I., Iyevleva, A. G., Bakholdin, D. V., Abysheva, S. N., Zavgorodnyaya, E. V., Potapova, O. N., Imyanitov, E. N., Ulitin, A. Y., & Matsko, D. E. (2011). ЗНАЧИМЫЙ РЕГРЕСС ГЛИОБЛАСТОМЫ С НИЗКОЙ ЭКСПРЕССИЕЙ ГЕНА MGMT ПРИ ХИМИОЛУЧЕВОЙ ТЕРАПИИ. Voprosy Onkologii, 57(2), 245-249.

Vancouver

Matsko MV, Luchin EI, Iyevleva AG, Bakholdin DV, Abysheva SN, Zavgorodnyaya EV и пр. ЗНАЧИМЫЙ РЕГРЕСС ГЛИОБЛАСТОМЫ С НИЗКОЙ ЭКСПРЕССИЕЙ ГЕНА MGMT ПРИ ХИМИОЛУЧЕВОЙ ТЕРАПИИ. Voprosy Onkologii. 2011 Июль 13;57(2):245-249.

Author

Matsko, M. V. ; Luchin, E. I. ; Iyevleva, A. G. ; Bakholdin, D. V. ; Abysheva, S. N. ; Zavgorodnyaya, E. V. ; Potapova, O. N. ; Imyanitov, E. N. ; Ulitin, A. Yu ; Matsko, D. E. / ЗНАЧИМЫЙ РЕГРЕСС ГЛИОБЛАСТОМЫ С НИЗКОЙ ЭКСПРЕССИЕЙ ГЕНА MGMT ПРИ ХИМИОЛУЧЕВОЙ ТЕРАПИИ. в: Voprosy Onkologii. 2011 ; Том 57, № 2. стр. 245-249.

BibTeX

@article{c2ca148e887e4e7badbb075079c5dd2c,
title = "ЗНАЧИМЫЙ РЕГРЕСС ГЛИОБЛАСТОМЫ С НИЗКОЙ ЭКСПРЕССИЕЙ ГЕНА MGMT ПРИ ХИМИОЛУЧЕВОЙ ТЕРАПИИ",
abstract = "Radiochemotherapy is leading the universal research effort in fighting lethality: it is improving relapse-free survival of patients with inoperable glioblastoma, the most pernicious brain tumor in adults. Its effectiveness was found to depend on expression of Mgmt gene of tumor DNA reparation following radiochemotherapy and adequate medication based on the molecular phenotype of tumor. Our study involved a 40-year old male with a low level of Mgmt gene expression as established by stereotactic biopsy. The patient received hypofractionated three-dimensional conformational proton therapy with the benefit of temozolomide (140 mg/24 hr). Subsequently, the dose was raised to 360 mg/24 hr, on days 1-5 of the cycle. Contrast-enhanced MRI examination established significant diminishing of the size of tumors on completion of cycles 7 and 8; patients felt better, memory and blood indices improved. As of the time this paper was written, relapse-free survival was 173 months, as compared with the literature data on inoperable glioblastoma - 5.5 months.",
author = "Matsko, {M. V.} and Luchin, {E. I.} and Iyevleva, {A. G.} and Bakholdin, {D. V.} and Abysheva, {S. N.} and Zavgorodnyaya, {E. V.} and Potapova, {O. N.} and Imyanitov, {E. N.} and Ulitin, {A. Yu} and Matsko, {D. E.}",
year = "2011",
month = jul,
day = "13",
language = "русский",
volume = "57",
pages = "245--249",
journal = "Вопросы онкологии",
issn = "0507-3758",
publisher = "Медицина",
number = "2",

}

RIS

TY - JOUR

T1 - ЗНАЧИМЫЙ РЕГРЕСС ГЛИОБЛАСТОМЫ С НИЗКОЙ ЭКСПРЕССИЕЙ ГЕНА MGMT ПРИ ХИМИОЛУЧЕВОЙ ТЕРАПИИ

AU - Matsko, M. V.

AU - Luchin, E. I.

AU - Iyevleva, A. G.

AU - Bakholdin, D. V.

AU - Abysheva, S. N.

AU - Zavgorodnyaya, E. V.

AU - Potapova, O. N.

AU - Imyanitov, E. N.

AU - Ulitin, A. Yu

AU - Matsko, D. E.

PY - 2011/7/13

Y1 - 2011/7/13

N2 - Radiochemotherapy is leading the universal research effort in fighting lethality: it is improving relapse-free survival of patients with inoperable glioblastoma, the most pernicious brain tumor in adults. Its effectiveness was found to depend on expression of Mgmt gene of tumor DNA reparation following radiochemotherapy and adequate medication based on the molecular phenotype of tumor. Our study involved a 40-year old male with a low level of Mgmt gene expression as established by stereotactic biopsy. The patient received hypofractionated three-dimensional conformational proton therapy with the benefit of temozolomide (140 mg/24 hr). Subsequently, the dose was raised to 360 mg/24 hr, on days 1-5 of the cycle. Contrast-enhanced MRI examination established significant diminishing of the size of tumors on completion of cycles 7 and 8; patients felt better, memory and blood indices improved. As of the time this paper was written, relapse-free survival was 173 months, as compared with the literature data on inoperable glioblastoma - 5.5 months.

AB - Radiochemotherapy is leading the universal research effort in fighting lethality: it is improving relapse-free survival of patients with inoperable glioblastoma, the most pernicious brain tumor in adults. Its effectiveness was found to depend on expression of Mgmt gene of tumor DNA reparation following radiochemotherapy and adequate medication based on the molecular phenotype of tumor. Our study involved a 40-year old male with a low level of Mgmt gene expression as established by stereotactic biopsy. The patient received hypofractionated three-dimensional conformational proton therapy with the benefit of temozolomide (140 mg/24 hr). Subsequently, the dose was raised to 360 mg/24 hr, on days 1-5 of the cycle. Contrast-enhanced MRI examination established significant diminishing of the size of tumors on completion of cycles 7 and 8; patients felt better, memory and blood indices improved. As of the time this paper was written, relapse-free survival was 173 months, as compared with the literature data on inoperable glioblastoma - 5.5 months.

UR - http://www.scopus.com/inward/record.url?scp=79960081148&partnerID=8YFLogxK

M3 - статья

C2 - 21809674

AN - SCOPUS:79960081148

VL - 57

SP - 245

EP - 249

JO - Вопросы онкологии

JF - Вопросы онкологии

SN - 0507-3758

IS - 2

ER -

ID: 39058443